Sinovac BiotechSVA
13F holders, Q4 2024 (December 31)4holders −5
0new positions
5sold out
$110.23avg. 13F price*
At the end of Q4 2024, 4 institutions reported holding Sinovac Biotech Ltd. (SVA) in their 13F filings, down 5 from Q3 2024. 0 opened new positions and 5 sold out. The largest holders were Orbimed Advisors LLC ($334.0M), Neumann Advisory Hong Kong Ltd ($2.0M) and Navellier & Associates Inc. ($0).
- Company
- Sinovac Biotech Ltd.
- CUSIP
- P8696W104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 5 | $76.3M |
All 13F filers, Q3 2024 → Q4 2024: 11,868,807 shares sold, net −11,868,807 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Orbimed Advisors LLC | 6.94% | No change | 2,718,735 | $334.0M |
| Neumann Advisory Hong Kong Ltd | 0.60% | No change | 315,586 | $2.0M |
| Navellier & Associates Inc. | 0.00% | No change | 14,167 | $0 |
| Financial Gravity Companies, Inc. | 0.00% | No change | 24 | $0 |
"% of holder's portfolio" is SVA's weight in each manager's 13F, not the share of Sinovac Biotech Ltd. the manager owns.